[go: up one dir, main page]

WO2014081029A1 - Agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anti-cancéreux - Google Patents

Agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anti-cancéreux Download PDF

Info

Publication number
WO2014081029A1
WO2014081029A1 PCT/JP2013/081665 JP2013081665W WO2014081029A1 WO 2014081029 A1 WO2014081029 A1 WO 2014081029A1 JP 2013081665 W JP2013081665 W JP 2013081665W WO 2014081029 A1 WO2014081029 A1 WO 2014081029A1
Authority
WO
WIPO (PCT)
Prior art keywords
erk
mek
inhibitor
administration
pkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/081665
Other languages
English (en)
Japanese (ja)
Inventor
升三 西田
正寛 椿
直希 小川
直寛 鈴山
唯史 谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kindai University
Original Assignee
Kindai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindai University filed Critical Kindai University
Priority to JP2014548630A priority Critical patent/JP6243850B2/ja
Publication of WO2014081029A1 publication Critical patent/WO2014081029A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Definitions

  • the present invention relates to a preventive, therapeutic or alleviating agent for peripheral neuropathy caused by an anticancer agent.
  • anti-cancer agents used in chemotherapy are inherently cytotoxic or cytotoxic, and include not only cancer (malignant tumor) cells but also human normal cells. Since side effects due to injury occur, it is important to administer to patients so that sufficient anticancer (anti-malignant tumor) effects are exhibited while preventing or reducing such side effects as much as possible.
  • Neuropathy associated with the administration of anticancer drugs is observed not only in the central nervous system, autonomic nervous system and peripheral nervous system but also in sensory organs such as taste. Among them, the frequency of occurrence is relatively high, and problems such as fulminant pain or burning pain, numbness of the extremities of the extremities, abnormal perception such as burning sensation, hypersensitivity such as hypersensitivity to a cold sensation, Peripheral nervous system neuropathy such as sensory abnormalities such as loss of sensation, numbness and discomfort, sensory ataxia, and weakness. Peripheral nervous system lesions caused by administration of this anticancer agent are thought to be mainly due to axonal degeneration.
  • Microtubules in axons play an important role in maintaining the normal function of cells, such as the formation of spindles during cell division, the arrangement of intracellular organelles and mass transport, but paclitaxel and docetaxel.
  • Taxane drugs such as vincristine, vinplastin, vindesine, vinorelbine, and other vinca alkaloid drugs act by targeting microtubules in the axon, thereby suppressing the growth of malignant tumor cells. It is believed that neuronal microtubules are also damaged and cause neuropathy.
  • platinum preparations such as oxaliplatin, carboplatin, cisplatin and nedaplatin and proteasome inhibitors such as portezomib are considered to cause secondary axonal damage as a result of directly damaging neurons.
  • neuropathy caused by anticancer drugs is an area where research has not progressed so much, and no method for preventing or symptom of neuropathy has been established.
  • vitamin preparations such as mecobalamin and Kampo-Kakjin-gan, a Kampo medicine, are used to relieve numbness, and antidepressants (amitriptine hydrochloride), antiepileptic drugs (carbamazepine), and antiarrhythmic drugs for pain.
  • antidepressants amitriptine hydrochloride
  • antiepileptic drugs carbamazepine
  • antiarrhythmic drugs for pain.
  • Mecobalamin and Kampo-Kakjin-gan a Kampo medicine
  • corticosteroids are used, but at present, there is no established cure or prevention method, and stopping or reducing the dose of the drug is the only certainty to stop neuropathy (However, neuropathy may persist or worsen after treatment is discontinued).
  • Non-patent Document 1 peripheral neuropathy in rats administered with oxaliplatin, a platinum-based drug, has been improved by intracerebroventricular administration of a PKC inhibitor (calphostin C)
  • calphostin C calphostin C
  • Non-Patent Document 2 administration of compounds that inhibit the MEK / ERK pathway (farnesylthiosalicylic acid and GW5074) into the subarachnoid space has improved peripheral neuropathy in rats administered with the pin alkaloid drug vincristine.
  • Non-Patent Document 2 shows that even by the methods of these documents, the improvement effect declined after 2 to 3 hours from the administration, and the continuous improvement could not be performed. The degree of improvement was also slight.
  • the administration is performed by a specialized surgical technique, and is performed by a method that cannot be easily performed on a daily basis. Thus, there is still no practical preventive, therapeutic or alleviating agent for peripheral neuropathy resulting from the administration of anticancer agents.
  • Non-Patent Document 1 mentions not only PKC but also ERK, the experimental result shows that the tendency of ERK phosphorylation is different from the tendency of PKC phosphorylation.
  • the relationship with the reduction of peripheral neuropathy has not been studied.
  • Non-Patent Document 2 describes that farnesyl thiosalicylic acid and GW5074 are inhibitors of the Ras / Raf / MEK / ERK2 signaling pathway, but these are described as inhibiting Ras and c-Raf-1. No mention is made of the relationship between inhibition of MEK or ERK and reduction of peripheral neuropathy.
  • an object of the present invention is to sufficiently and continuously prevent, treat, or reduce peripheral neuropathy caused by an anticancer agent.
  • the present inventors show that non-local administration of a PKC inhibitor or a MEK / ERK pathway inhibitor can sufficiently and continuously suppress peripheral neuropathy caused by an anticancer agent. I found it.
  • the PKC inhibitor or MEK / ERK pathway inhibitor was locally administered into the ventricle or the intrathecal space, etc., and the improvement effect was not sustained, and this finding was partial. It is technological. Since non-local administration can be performed by a simple method such as oral administration, it is possible to prevent, treat, or alleviate by a simple method in a daily environment such as home. It is technological.
  • the present inventors have found that the sufficient and sustained suppression effect found in PKC inhibitors or MEK / ERK pathway inhibitors is due to inhibition of MEK or ERK.
  • PKC inhibition and MEK / ERK pathway inhibition there are descriptions of PKC inhibition and MEK / ERK pathway inhibition, but there is no mention of MEK or ERK inhibition, and the findings of the present inventors are novel.
  • the present inventors have been able to prevent peripheral neuropathy caused by administration of the anticancer agent. It has been found that prevention, treatment or alleviation can be carried out sufficiently and continuously with another anticancer agent. This finding is an epoch-making in that peripheral neuropathy caused by the administration of anticancer drugs is adequately and sustainedly prevented, treated, or reduced by devising combinations of anticancer drugs in combination therapy. It provides ideas.
  • the present invention provides a preventive, therapeutic or alleviating agent for non-local administration of peripheral neuropathy caused by an anticancer agent, which contains a PKC inhibitor or MEK / ERK pathway inhibitor as an active ingredient.
  • the present invention provides an agent for preventing, treating, or alleviating peripheral neuropathy with an anticancer agent, which contains a MEK inhibitor or ERK inhibitor as an active ingredient.
  • the present invention provides the above-mentioned preventive, therapeutic or alleviating agent, wherein the MEK inhibitor or ERK inhibitor is an anticancer agent.
  • the present invention also provides the aforementioned preventive, therapeutic, or alleviating agent, wherein the ERK inhibitor is an ERK phosphorylation inhibitor.
  • the present invention provides the prevention, treatment, wherein the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, and ERK2 Tyr187, Or provide a mitigation agent.
  • the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, and ERK2 Tyr187, Or provide a mitigation agent.
  • the present invention also provides the preventive, therapeutic or alleviating agent described above, wherein the peripheral neuropathy is caused by a platinum preparation.
  • the present invention includes a step for evaluating PKC inhibition or MEK / ERK pathway inhibition by a subject, a preventive, therapeutic or alleviating agent for non-local administration of peripheral neuropathy by an anticancer agent, A method for selecting an active ingredient is provided.
  • the present invention also provides a method for selecting an active ingredient for prevention, treatment, or alleviation of peripheral neuropathy with an anticancer agent, comprising the step of evaluating MEK inhibition or ERK inhibition by a test subject. To do.
  • the present invention relates to a method for preventing, treating or alleviating peripheral neuropathy with an anticancer agent, characterized by non-locally administering a PKC inhibitor or a MEK / ERK pathway inhibitor. Is to provide.
  • the present invention also provides a method for preventing, treating or alleviating peripheral neuropathy with an anticancer agent, which comprises administering a MEK inhibitor or an ERK inhibitor.
  • the present invention provides the prevention, treatment, or alleviation method described above, wherein the MEK inhibitor or ERK inhibitor is an anticancer agent.
  • the present invention provides the prevention, treatment or alleviation method described above, wherein the ERK inhibitor is an ERK phosphorylation inhibitor.
  • the present invention relates to the prevention, treatment, or treatment described above, wherein the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, ERK2 Tyr187, or It provides a mitigation method.
  • the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, ERK2 Tyr187, or It provides a mitigation method.
  • the present invention provides the prevention, treatment or alleviation method described above, wherein the peripheral neuropathy is caused by a platinum preparation.
  • the present invention provides a use of a PKC inhibitor or a MEK / ERK pathway inhibitor for producing a preventive, therapeutic, or alleviating agent for non-local administration of peripheral neuropathy caused by an anticancer agent. Is to provide.
  • the present invention provides the use of a MEK inhibitor or ERK inhibitor for producing a preventive, therapeutic or alleviating agent for peripheral neuropathy with an anticancer agent.
  • the present invention provides the above use, wherein the MEK inhibitor or ERK inhibitor is an anticancer agent.
  • the present invention also provides the use described above, wherein the ERK inhibitor is an ERK phosphorylation inhibitor.
  • the present invention also provides the use as described above, wherein the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, ERK2 Tyr187. It is.
  • the present invention also provides the use as described above, wherein the peripheral neuropathy is caused by a platinum preparation.
  • the present invention provides a non-topical use of a PKC inhibitor or MEK / ERK pathway inhibitor for the prevention, treatment or alleviation of peripheral neuropathy by an anticancer agent. It is.
  • the present invention also provides use of a MEK inhibitor or ERK inhibitor for the prevention, treatment, or alleviation of peripheral neuropathy with an anticancer agent.
  • the present invention also provides the use as described above, wherein the MEK inhibitor or ERK inhibitor is an anticancer agent.
  • the present invention also provides the use described above, wherein the ERK inhibitor is an ERK phosphorylation inhibitor.
  • the present invention also provides the use as described above, wherein the ERK inhibitor is a phosphorylation inhibitor of a phosphorylation site selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, ERK2 Tyr187. It is.
  • the present invention also provides the use as described above, wherein the peripheral neuropathy is caused by a platinum preparation.
  • peripheral neuropathy caused by an anticancer agent can be prevented, treated, or alleviated extremely highly and continuously. That is, by administering the preventive, therapeutic, or alleviating agent of the present invention, limb numbness, extremity pain, deep tendon reflex reduction, muscle strength reduction, allodynia, hyperalgesia, fingers It is possible to prevent, treat or alleviate dexterous dysfunction, gait disorder, whispering, falling, flexion disorder (difficult or impossible of sitting, cross-legged, side-sitting or chair-sitting), or paralysis of limbs.
  • the preventive, therapeutic, or alleviating agent of the present invention can be administered non-locally by oral administration or the like, and can easily prevent or treat peripheral neuropathy caused by an anticancer agent in a daily environment such as home. Or can be reduced. This improves the quality of life for patients who receive home-treated anticancer drug treatment.
  • an anticancer agent different from the anticancer agent causing peripheral neuropathy is used as the active ingredient of the preventive, therapeutic or alleviating agent of the present invention
  • prevention, treatment or improvement of peripheral neuropathy is performed. This can be easily performed in combination therapy with anticancer agents.
  • an active ingredient is selected using an indicator that it is an anticancer drug, it can be used in combination with multiple drugs without requiring long-term clinical trials by using existing information on effective dose, effective administration method, side effects, etc.
  • Peripheral neuropathy prophylactic, therapeutic or alleviating agents that can be used clinically in therapy can be easily and rapidly manufactured.
  • FIG. 1 shows the results of examining the alleviation effect of a test drug on hypersensitivity caused by oxaliplatin administration in the von Frey test.
  • FIG. 2 shows the results of examining the reducing effect of the test drug on the sensory abnormality caused by oxaliplatin administration in the cold plate test.
  • FIG. 3 shows the results of examining the inhibitory effect of the test drug on the increased expression of phosphorylated ERK and phosphorylated PKC in the spinal cord on the 14th day after oxaliplatin administration. The figure shows the results of one representative experiment of at least three independent experiments.
  • FIG. 4 shows the results of examining the alleviation effect of the test drug on the hypersensitivity caused by oxaliplatin administration in the von Frey test.
  • FIG. 4 shows the results of examining the alleviation effect of the test drug on the hypersensitivity caused by oxaliplatin administration in the von Frey test.
  • FIG. 5 shows the results of examining the reducing effect of the test drug on the sensory abnormality caused by oxaliplatin administration in the cold plate test.
  • FIG. 6 shows the results of examining the inhibitory effect of the test drug on the increased expression of phosphorylated ERK and phosphorylated PKC in the spinal cord on the 14th day after oxaliplatin administration.
  • PKC inhibitor is an active ingredient of the preventive, therapeutic or alleviating agent of the present invention.
  • PKC is also referred to as protein kinase C.
  • PKC include PKC- ⁇ , PKC- ⁇ 1, PKC- ⁇ 2, PKC- ⁇ , PKC- ⁇ , PKC- ⁇ , PKC- ⁇ , PKC- ⁇ , PKC- ⁇ , PKC- ⁇ , and PKC- ⁇ . It is done.
  • a PKC inhibitor is a substance having an action of inhibiting PKC. As an effect
  • the action of inhibiting PKC phosphorylation is preferably an action of reducing the expression level of phosphorylated PKC without substantially reducing the expression level of PKC.
  • a substance having an action of inhibiting PKC phosphorylation can be referred to as a PKC phosphorylation inhibitor.
  • PKC phosphorylation sites include Ser638 for PKC- ⁇ , and Ser643 and Thr505 for PKC- ⁇ .
  • the PKC inhibitor may be cell permeable.
  • the PKC inhibitor may be an inorganic compound or an organic compound, and examples of the organic compound include organic compounds having 10 to 100 carbon atoms.
  • the MEK / ERK pathway inhibitor is an active ingredient of the preventive, therapeutic or alleviating agent of the present invention.
  • MEK is also referred to as mitogen activated protein kinase kinase.
  • ERK is also referred to as extra cellular signal regulated kinase. Examples of MEK include MEK1 and MEK2.
  • ERK includes ERK1, ERK2, and ERK1 / 2.
  • ERK1 / 2 is a complex consisting of ERK1 and ERK2.
  • the MEK / ERK pathway inhibitor is a substance having an action of inhibiting the MEK / ERK pathway.
  • the MEK / ERK pathway is a signal transduction pathway involving MEK and ERK.
  • MEK / ERK pathway inhibitors examples include MEK inhibitors such as MEK1 inhibitors and MEK2 inhibitors; ERK inhibitors such as ERK1 inhibitors and ERK2 inhibitors.
  • the ERK1 inhibitor and the ERK2 inhibitor may be an ERK1 / 2 inhibitor that is an inhibitor of a complex composed of ERK1 and ERK2.
  • the MEK / ERK pathway inhibitor may be cell permeable.
  • the MEK / ERK pathway inhibitor may be an inorganic compound or an organic compound, and examples of the organic compound include organic compounds having 10 to 100 carbon atoms.
  • MEK / ERK pathway inhibitors include AG 126, apigenin, FR180204, 5-iodotubercidine, 5-nitro-2- (3-phenylpropylamino) benzoic acid, PD98059, U0125, U0126, and their derivatives, Pharmaceutically acceptable salts, and the like.
  • MEK inhibitor is an active ingredient of the preventive, therapeutic or alleviating agent of the present invention.
  • the MEK inhibitor is a substance having an action of inhibiting MEK.
  • Examples of MEK inhibitors include ATP competitive MEK inhibitors, non-ATP competitive MEK inhibitors, and ATP non-competitive MEK inhibitors.
  • action which inhibits MEK the effect
  • the action of inhibiting the phosphorylation of MEK is preferably the action of reducing the expression level of phosphorylated MEK without substantially reducing the expression level of MEK.
  • a substance having an action of inhibiting MEK phosphorylation can be referred to as MEK phosphorylation inhibitor.
  • MEK inhibitors include substances that inhibit MEK in the spinal cord of animals. Examples of the spinal cord include the lumbar spinal cord.
  • the MEK inhibitor is more preferable because it can inhibit the MEK / ERK pathway more specifically and does not affect other signal transduction pathways, and thus has few side effects.
  • MEK inhibitors are preferable in that they can suppress peripheral neuropathy.
  • Examples of MEK inhibitors include MEK inhibitors of benzimidazole derivatives, MEK inhibitors of benzamide derivatives, MEK inhibitors of pyridazine derivatives, and MEK inhibitors of benzopyran derivatives. More specifically, examples of MEK inhibitors include, for example, trametinib, selumetinib, refametinib, pimasertib, MEK162 / ARRYDC-4, AZD8330 / ARRG-4070 / ARRG-4070 RG7420, GDC-0623 / RG7421 / XL518, CIF / RG7167 / RO4987655, CK127 / RG7304 / RO5126766, E6201, TAK-733, PD-0325901, AS703888 / MSC2015103B, WX-554, and derivatives thereof, pharmaceutically acceptable And the like, and the like.
  • the ERK inhibitor is an active ingredient of the preventive, therapeutic or alleviating agent of the present invention.
  • An ERK inhibitor is a substance having an action of inhibiting ERK.
  • action which inhibits ERK the effect
  • the action of inhibiting the phosphorylation of ERK is preferably the action of reducing the expression level of phosphorylated ERK without substantially reducing the expression level of ERK.
  • a substance having an action of inhibiting ERK phosphorylation can be referred to as an ERK phosphorylation inhibitor.
  • Examples of the phosphorylation site of ERK include Thr202 and Tyr204 for ERK1, and Thr185 and Tyr187 for ERK2.
  • Examples of the phosphorylation inhibitor of ERK include phosphorylation inhibitors of phosphorylation sites selected from the group consisting of ERK1 Thr202, ERK1 Tyr204, ERK2 Thr185, and ERK2 Tyr187.
  • ERK inhibitors include substances that inhibit ERK in the spinal cord of animals. Examples of the spinal cord include the lumbar spinal cord.
  • the PKC inhibitor, MEK / ERK pathway inhibitor, MEK inhibitor, or ERK inhibitor may be an anti-estrogen agent.
  • Antiestrogens include steroidal antiestrogens and nonsteroidal antiestrogens.
  • An anti-estrogen agent is a substance that binds to an estrogen receptor and exerts an antagonistic action against estrogen.
  • Mepithiostan is a steroidal antiestrogen.
  • Tamoxifen is a non-steroidal anti-estrogen agent.
  • PKC inhibitors, MEK / ERK pathway inhibitors, MEK inhibitors, or ERK inhibitors may be tamoxifen analogs (also referred to as tamoxifen analogs).
  • Tamoxifen analogs include non-steroidal antiestrogens such as clomiphene and toremifene; selective estrogen modulators such as raloxifene, apeledoxifene, arzoxifene, lasofoxifene; tamoxifen such as 4-hydroxytamoxifen and endoxifen Active metabolites.
  • a PKC inhibitor, MEK / ERK pathway inhibitor, MEK inhibitor, or ERK inhibitor includes a drug having a function as an anticancer agent.
  • a PKC inhibitor, MEK / ERK pathway inhibitor, MEK inhibitor, or ERK inhibitor that is an anticancer agent may be used as an active ingredient.
  • it is possible to easily prevent, treat, or reduce peripheral neuropathy caused by anticancer drugs by devising combinations of anticancer drugs in combination therapy using multiple anticancer drugs.
  • clinical use can be rapidly started by using information such as known side effects, dosage, administration method, pharmacological test data, etc., regarding the anticancer agent to be used.
  • the active ingredient of the preventive, therapeutic, or alleviating agent of the present invention may contain only one PKC inhibitor, MEK / ERK pathway inhibitor, MEK inhibitor, or ERK inhibitor, or two or more PKC inhibitors Agents, MEK / ERK pathway inhibitors, MEK inhibitors, or ERK inhibitors may be included.
  • anticancer agents that cause peripheral neuropathy include microtubule inhibitors such as anticancer agents that damage microtubules and cause peripheral neuropathy.
  • anticancer agents include taxane drugs such as paclitaxel and docetaxel; and vinca alkaloid drugs such as vincristine, vinplastin, vindesine, and vinorelbine.
  • anticancer agent that causes peripheral neuropathy include an anticancer agent that causes peripheral neuropathy by causing axonal damage by damaging nerve cells.
  • anticancer agents include platinum preparations such as oxaliplatin, carboplatin, cisplatin and nedaplatin; and proteasome inhibitors such as bortezomip.
  • peripheral neuropathy caused by these anticancer agents include hypersensitivity, sensory abnormalities, sensory abnormalities, and acute or chronic pain. More specifically, as hypersensitivity, hyperalgesia such as allodynia caused by mechanical stimulation can be mentioned. Allodynia means severe pain caused by tactile stimuli that do not usually cause pain. More specifically, the abnormal sensation includes abnormal sensation due to low-temperature stimulation, numbness of the extremities, burning sensation, and the like. Sensory abnormalities include loss of sensation, numbness, and discomfort. As a site where sensory paralysis occurs, limbs may be mentioned. A limb is mentioned as a site where acute or chronic pain occurs. Pain includes what is called fulminant pain, burning pain.
  • peripheral neuropathy may cause problems in daily life such as motor dysfunction and a decrease in deep tendon reflexes.
  • motor dysfunction include muscle weakness and ataxia.
  • ataxia include finger skillful dysfunction, flexion disorder, and walking disorder. Skillful dysfunction of fingers may be accompanied by obstacles such as difficulty in grasping objects and difficulty in pressing buttons.
  • the flexion disorder include a state where sitting, cross-legs, side-sitting or chair-sitting is difficult or impossible. Gait disturbance may involve whispering, falling, etc.
  • peripheral neuropathy caused by an anticancer agent to be prevented, treated, or alleviated is not only caused by monotherapy using one type of anticancer agent, but also a plurality of different action mechanisms. Also included are peripheral neuropathies that occur in combination therapy in which drugs are administered in combination, and peripheral neuropathies that occur in biochemical modulation therapy.
  • Biochemical modulation therapy is a therapy in which a combination of drugs or a method for administering drugs is devised so that drugs with different mechanisms of action can exert their maximum effectiveness.
  • peripheral neuropathy that occurs in FOLFOX therapy is also included in the subject of prevention, treatment, or alleviation in the present invention.
  • FOLFOX therapy is a cancer chemotherapy using a combination of fluorouracil, folinic acid, and oxaliplatin, and is one type of chemotherapy for colorectal cancer.
  • the present invention can prevent, treat, or alleviate these peripheral neuropathies, where “prevention” includes preventing, suppressing, and delaying the onset of a disease state. Shall be. “Treatment” includes not only the complete cure of the disease state, but also the suppression of the progression or worsening of symptoms that are not completely cured, but the progression of the disease state and the improvement of part or all of the disease state. It shall be included to guide the direction of healing. Further, “relieving” includes alleviating symptoms.
  • the preventive, therapeutic, or alleviating agent of the present invention includes, in addition to active ingredients, excipients, binders, lubricants, disintegrants, corrigents, flavoring agents, surfactants, fragrances, coloring agents, and antioxidants. , Additives such as masking agents, antistatic agents, fluidizing agents, wetting agents and the like may be included.
  • excipients include glucose, fructose, maltose, lactose, isomerized lactose, reduced lactose, sucrose, D-mannitol, erythritol, maltitol, xylitol, palatinose, trehalose, sorbitol, corn starch, potato starch, wheat Starch, rice starch, crystalline cellulose, talc, anhydrous silicic acid, anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, dextran (eg, dextran, dextran 40, dextran 70, etc.), pullulan, dextrin, pregelatinized starch, etc. .
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, polyvinylpyrrolidone, methylcellulose, polyvinyl alcohol, carboxymethylcellulose, partially pregelatinized starch, pregelatinized starch, sodium alginate, pullulan, gum arabic powder, gelatin, dextrin, etc. These may be used by appropriately blending one or more of these.
  • lubricant examples include magnesium stearate, calcium stearate, sucrose fatty acid ester, sodium stearyl fumarate, stearic acid, talc, polyethylene glycol and the like.
  • disintegrant examples include low-substituted hydroxypropyl cellulose, carmellose, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, hydroxypropyl starch, and corn starch.
  • examples of the corrigent include sucrose, D-sorbitol, xylitol, citric acid, ascorbic acid, tartaric acid, malic acid, aspartame, acesulfame potassium, thaumatin, sodium saccharine, dipotassium glycyrrhizin, sodium glutamate, 5′-sodium inosinate, 5 '-Sodium guanylate and the like can be mentioned.
  • Examples of the flavoring agent include trehalose, malic acid, maltose, potassium gluconate, anise essential oil, vanilla essential oil, and cardamom essential oil.
  • Examples of the surfactant include polysorbate (polysorbate 80 and the like), polyoxyethylene / polyoxypropylene copolymer, sodium lauryl sulfate, and the like.
  • Examples of the fragrances include lemon oil, orange oil, menthol and brackish oil.
  • Examples of the colorant include titanium oxide, edible yellow No. 5, edible blue No. 2, iron sesquioxide, yellow sesquioxide.
  • Examples of the antioxidant include sodium ascorbate, L-cysteine, sodium sulfite, vitamin E and the like.
  • Examples of the concealing agent include titanium oxide.
  • antistatic agent examples include talc and titanium oxide.
  • fluidizing agent examples include light anhydrous silicic acid, talc, hydrous silicon dioxide and the like.
  • wetting agent examples include polysorbate 80, sodium laurate sulfate, sucrose fatty acid ester, macrogol, and hydroxypropyl cellulose (HPC).
  • additives can be blended in a proportion usually used for the intended preparation.
  • additives such as those described in publicly known documents, for example, edited by Yakuji Nippo Co., Ltd., 2000 “Pharmaceutical Additives Dictionary” edited by the Japan Pharmaceutical Additives Association) may be used.
  • Examples of the dosage form of the preventive, therapeutic, or alleviating agent of the present invention include, but are not limited to, solid preparations, such as aerosols, liquids, extracts, soft extracts, dry extracts, elixirs, Capsules, hard capsules, soft capsules, granules, pills, eye ointments, transdermal preparations, suspensions, emulsions, suppositories, powders, spirits, tablets, syrups, soaking agents, decoction, Examples include injections, patches, tinctures, eye drops, lozenges, ointments, poultices, fragrances, liniments, limonades, fluid extracts, and lotions.
  • solid preparations such as aerosols, liquids, extracts, soft extracts, dry extracts, elixirs, Capsules, hard capsules, soft capsules, granules, pills, eye ointments, transdermal preparations, suspensions, emulsions
  • the preventive, therapeutic or alleviating agent of the present invention can be produced by a known method.
  • a granular solid preparation can be produced by granulation using a tumbling granulator, a stirring granulator, a fluidized granulator, a centrifugal tumbling granulator, a dry granulator or the like.
  • the capsule can be produced by a known method.
  • a hard capsule for example, a gelatin capsule, a hydroxypropyl methylcellulose (HPMC) capsule, a pullulan, and the like added with additives as necessary to the granules).
  • Tablets can also be produced by a known method.
  • the above granules and, if necessary, the additives are mixed evenly, compression-molded by a rotary tableting machine or the like to obtain an uncoated tablet, and the uncoated tablet is used as a tablet as it is, or as necessary
  • a tablet can be produced by coating with a coating base.
  • a tablet can also be produced by preparing a mixed powder containing a drug and the like without granulation and tableting it with a rotary tableting machine or the like.
  • the active ingredient and excipient are dissolved in a solvent (for example, water, an organic solvent (for example, ethanol, acetone, etc.), or a mixed solvent thereof), and lyophilized by lyophilization according to a conventional method.
  • a solvent for example, water, an organic solvent (for example, ethanol, acetone, etc.), or a mixed solvent thereof.
  • the dose of the active ingredient of the preventive, therapeutic, or alleviating agent of the present invention varies depending on the age, weight, pathological condition, administration method, etc. of the patient receiving the administration. For example, 20-40 mg per administration in the patient receiving the administration This may be administered, for example, once every half day to once every two days.
  • the frequency of administration of the preventive, therapeutic, or alleviating agent of the present invention varies depending on the age, weight, disease state, method of administration, etc. of the patient receiving the administration. For example, the frequency of administration of anticancer agents causing peripheral neuropathy is 3 to 10 times.
  • the dose of the active ingredient of the preventive, therapeutic, or alleviating agent of the present invention is such that, for example, the blood concentration of the patient receiving the administration is 100 ng / mL to 800 ng / mL, more specifically 100 ng / mL to The amount is 200 ng / mL.
  • the preventive, therapeutic or alleviating agent of the present invention containing a PKC inhibitor or MEK / ERK pathway inhibitor as an active ingredient is administered to a patient by non-local administration.
  • Local administrations that are excluded in non-local administration include intrathecal administration, such as intraventricular administration, intrathecal administration.
  • Non-local administration includes oral administration, tube feeding, enteral administration such as enema administration; intravenous administration such as intravenous injection and intravenous infusion; transarterial administration; intramuscular administration; subcutaneous administration; Skin administration; transmucosal administration; intraosseous administration may be used.
  • oral administration and transdermal administration are excellent in that they can be easily used in a daily environment.
  • the administration route of the preventive, therapeutic, or alleviating agent of the present invention containing a MEK inhibitor or ERK inhibitor as an active ingredient includes dermal administration, inhalation administration, enema administration, ear-dropping, nasal administration, and intravaginal administration.
  • Patients to whom the preventive, therapeutic or alleviating agent of the present invention is administered include ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, endometrial cancer, head and neck cancer, esophageal cancer, leukemia, malignant lymphoma, Childhood tumor, multiple myeloma, malignant astrocytoma, glioma, choriocarcinoma, germ cell tumor, testicular tumor, bladder cancer, renal pelvis tumor, ureteral tumor, prostate cancer, cervical cancer, neuroblast Examples include cancer patients suffering from one or more types of cancer selected from the group consisting of cell tumors, small cell lung cancer, osteosarcoma, malignant pleural mesothelioma, malignant bone tumor, and colon cancer.
  • peripheral neuropathy caused by an anticancer agent is that a PKC inhibitor or MEK / ERK pathway inhibitor is administered non-locally, or MEK or ERK is inhibited.
  • peripheral neuropathy caused by an anticancer agent by performing a step of evaluating PKC inhibition or MEK / ERK pathway inhibition by a test substance, or by performing a step of evaluating MEK inhibition or ERK inhibition by a test substance
  • the active ingredient of the preventive, therapeutic or alleviating agent can be selected.
  • the present invention includes the step of evaluating PKC inhibition or MEK / ERK pathway inhibition by a test subject, which is characterized by prevention, treatment, or alleviation for non-local administration of peripheral neuropathy caused by an anticancer agent.
  • a method is also provided.
  • test substance is a substance that is a candidate for an active ingredient to be selected.
  • the test object may be an organic compound or an inorganic compound derived from a natural product, or may be a synthetic organic compound or an inorganic compound.
  • the step of evaluating PKC inhibition or MEK / ERK pathway inhibition by a subject and the step of evaluating MEK inhibition or ERK inhibition by a subject may be performed by an in vivo test or an in vitro test.
  • In vivo testing may be performed, for example, by a test comprising administering a test substance to a model organism and comparing PKC, MEK, or ERK in the model organism before and after administration of the test substance.
  • the step of comparing PKC, MEK, or ERK in the model organism before and after the administration of the test subject is the step of measuring PKC, MEK, or ERK in the model organism before and after the test subject administration, and the measurement May be performed by comparing PKC, MEK, or ERK before and after administration.
  • the PKC, MEK, or ERK in the model organism to be measured include the expression level of PKC, MEK, or ERK protein, the degree of phosphorylation of PKC, MEK, or ERK.
  • the degree of phosphorylation of PKC, MEK, or ERK can be measured by using a phosphorylation-specific recognition antibody, for example, the expression level of phosphorylated PKC, MEK, or ERK protein.
  • a phosphorylation-specific recognition antibody for example, the expression level of phosphorylated PKC, MEK, or ERK protein.
  • the phosphorylated PKC, MEK, or ERK protein to be measured include PKC- ⁇ protein phosphorylated by Ser638; PKC- ⁇ protein phosphorylated by Ser643 or Thr505; Thr202 or Tyr204 site is phosphorylated ERK1 protein; ERK2 protein phosphorylated at Thr185 or Tyr187 site; phosphorylation site selected from the group consisting of Thr202 of ERK1 protein, Tyr204 of ERK1 protein, Thr185 of ERK2 protein, and Tyr187 of ERK2 protein Examples include ERK1 / 2 protein.
  • the phosphorylation site in phosphorylated PKC, MEK, or ERK protein to be measured may be single or plural.
  • Examples of PKC, MEK, or ERK in the model organism to be measured include PKC, MEK, or ERK in the spinal cord of the model organism, and in particular, PKC, MEK, or ERK in the lumbar spinal cord.
  • Examples of model organisms used in the test include mammals, and examples of mammals include humans and non-human mammals such as rats and mice.
  • the selection of an active ingredient for prevention, treatment, or alleviation of peripheral neuropathy by an anticancer agent is PKC inhibition, MEK / ERK pathway inhibition, MEK inhibition, or ERK by the subject. This is based on the result of evaluating inhibition.
  • the selection of the active ingredient of the preventive, therapeutic, or alleviating agent may be based solely on the results of evaluating PKC inhibition, MEK / ERK pathway inhibition, MEK inhibition, or ERK inhibition by the subject, but depending on the subject It may be based on an evaluation performed by combining the result of evaluating PKC inhibition, MEK / ERK pathway inhibition, MEK inhibition, or ERK inhibition with other information on the test substance. Other information about the subject includes other in vivo or in vitro test results for the subject.
  • the method for selecting an active ingredient in the present invention may be performed for a single test object or may be performed in a high content screening system using a plurality of test objects.
  • Example 1 Effect of oxaliplatin on mouse peripheral neuropathy: The test drug is orally administered to mice as described below, and the cold plate test and the von Frey test are performed. The efficacy of the test drug on hypersensitivity and sensory abnormalities in cold stimulation was investigated.
  • Test drug administration 6-7 week old Balb / c male mice were used as experimental animals, and the control group, the oxaliplatin administration group, and the oxaliplatin and test drug administration group (hereinafter also simply referred to as oxaliplatin + test drug administration group) It was organized into groups. In the oxaliplatin administration group, once a week intravenous administration of oxaliplatin was continued for 2 weeks, and oxaliplatin was administered twice in total. The single dose of oxaliplatin was 6 mg / kg relative to the body weight of the mouse.
  • tamoxifen was orally administered as the test drug 14 times in total, continuously for 2 weeks immediately after oxaliplatin administration.
  • the single dose of tamoxifen was 30 mg / kg relative to the body weight of the mouse.
  • the control group was administered with 5% glucose solution and physiological saline.
  • the solvent used for administration to the oxaliplatin administration group and the oxaliplatin + test drug administration group was also 5% glucose solution and physiological saline.
  • Test Example 1 Measurement of ERK inhibitory action: Western blot analysis was performed on lumbar spinal cord samples collected from mice 14 days after the start of the experiment, and the expression levels of ERK protein and phosphorylated ERK protein in the samples were examined. The phosphorylated ERK protein test was performed using an antibody (Phospho-p44 / 42MAPK (ERK1 / 2) that recognizes phosphorylation of a phosphorylation site selected from the group consisting of Thr202 of ERK1, Tyr204 of ERK1, Thr185 of ERK2, and Tyr187 of ERK2. ) (Thr202 / Tyr204) Antibody; Cell Signaling Technology). ⁇ -actin was used as a control.
  • an antibody Phospho-p44 / 42MAPK (ERK1 / 2) that recognizes phosphorylation of a phosphorylation site selected from the group consisting of Thr202 of ERK1, Tyr204 of ERK1, Thr185 of ERK2, and Tyr187 of ERK
  • Test Example 2 Measurement of PKC inhibitory action: The same test as in Test Example 1 was performed, and the expression levels of phosphorylated PKC- ⁇ (Ser638), phosphorylated PKC- ⁇ (Ser643), and phosphorylated PKC- ⁇ (Thr505) in the thoracic spinal cord samples were examined. The results are shown in FIG. As shown in FIG. 3, in the oxaliplatin + test drug administration group administered with oxaliplatin in combination with the test drug, the expression level of phosphorylated PKC was significantly suppressed as compared with the oxaliplatin administration group. From this, it is clear that peripheral neuropathy caused by anticancer agents such as oxaliplatin can be prevented, treated, or alleviated continuously and non-locally by administering a PKC inhibitor. became.
  • Example 2 Effect of MEK inhibitor: A von Frey test and a cold plate test were performed in the same manner as in Example 1 except that PD0325901 was used as a test drug.
  • PD0325901 is a MEK inhibitor that selectively binds to MEK and inhibits MEK in a non-ATP competitive manner.
  • MEK is located upstream of ERK in the MEK / ERK pathway. The results are shown in FIGS. 4 and 5, respectively. As shown in FIGS. 4 and 5, as in Example 1, the mechanical stimulus suppression effect and the cold stimulus suppression effect by the test drug were recognized.
  • test Example 1 the same test as in Test Example 1 was performed to examine the expression level of ERK protein and the expression level of phosphorylated ERK protein in the sample. The results are shown in FIG. As shown in FIG. 6, as in Test Example 1, the effect of suppressing the phosphorylated ERK expression level by the test drug was observed.
  • Test Example 3 Safety measurement: For the three groups in the test of Example 1 and the three groups in the test of Example 2, changes in body weight of the mice used in the test were measured over time. As a result, there was no significant difference in body weight change in any group, and it was found that the preventive, therapeutic or alleviating agent of the present invention had few side effects and high safety.
  • test drug was used as an indicator of peripheral neuropathy, with hypersensitivity such as allodynia caused by mechanical stimulation caused by administration of anticancer drugs such as oxaliplatin, and sensory abnormalities caused by low-temperature stimulation.
  • hypersensitivity such as allodynia caused by mechanical stimulation caused by administration of anticancer drugs such as oxaliplatin
  • sensory abnormalities caused by low-temperature stimulation.
  • peripheral neuropathy has an excellent preventive, therapeutic or alleviating action continuously.
  • PKC inhibitors or MEK inhibitors inhibit MEK or inhibit phosphorylation of ERK, inhibit ERK, and inhibit the MEK / ERK pathway. It has been observed that it has sustained good preventive, therapeutic, or alleviating effects.
  • peripheral neuropathy such as abnormalities and sensory abnormalities, can be continually and significantly prevented, treated, or alleviated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne la prévention, le traitement ou le soulagement de troubles nerveux périphériques causés par des agents anticancéreux de manière satisfaisante et durable. La présente invention concerne un agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anticancéreux, ledit agent prophylactique, thérapeutique ou de soulagement étant destiné à être administré par voie non topique et contenant un inhibiteur de PKC ou un inhibiteur de la voie MEK/ERK en tant que substance active. La présente invention concerne en outre un agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anticancéreux, ledit agent prophylactique, thérapeutique ou de soulagement contenant un inhibiteur de MEK ou un inhibiteur de ERK en tant que substance active.
PCT/JP2013/081665 2012-11-26 2013-11-25 Agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anti-cancéreux Ceased WO2014081029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014548630A JP6243850B2 (ja) 2012-11-26 2013-11-25 抗がん剤による末梢神経障害の予防、治療、または軽減剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-257605 2012-11-26
JP2012257605 2012-11-26

Publications (1)

Publication Number Publication Date
WO2014081029A1 true WO2014081029A1 (fr) 2014-05-30

Family

ID=50776204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/081665 Ceased WO2014081029A1 (fr) 2012-11-26 2013-11-25 Agent prophylactique, thérapeutique ou soulageant des troubles nerveux périphériques causés par des agents anti-cancéreux

Country Status (2)

Country Link
JP (1) JP6243850B2 (fr)
WO (1) WO2014081029A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
IL140716A0 (en) * 1998-07-06 2002-02-10 Use of inhibitors of protein kinase c epsilon to treat pain
WO2002102232A2 (fr) * 2001-06-14 2002-12-27 The Regents Of The University Of California Nouvelle voie de signalisation destinee a la production de douleur inflammatoire et de neuropathie
US20150158948A9 (en) * 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"4-Methylcatechol ameliorates chronic pain concurrent with mood disorder by inducing brain -derived neurotrophic factor", THE JOURNAL OF PAIN, vol. 13, no. 4, April 2012 (2012-04-01), pages S39 *
JAGGI, AS. ET AL.: "Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats", FOOD CHEM TOXICOL, vol. 50, no. 5, May 2012 (2012-05-01), pages 1295 - 301 *
NORCINI, M. ET AL.: "Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat", PAIN, vol. 146, 2009, pages 141 - 147 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Also Published As

Publication number Publication date
JPWO2014081029A1 (ja) 2017-01-05
JP6243850B2 (ja) 2017-12-06

Similar Documents

Publication Publication Date Title
AU2012321110B2 (en) Combination treatment
Heist et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
IL311471A (en) Combination therapy
US11033532B2 (en) Uses of benzimidazole derivative for nocturnal acid breakthrough
JP2012515184A (ja) 大腸がんの治療方法
JP7041322B2 (ja) ２，３，５－置換されたチオフェン化合物の乳癌の予防、改善または治療用途
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
AU2016279096B2 (en) Composition containing carboplatin and use
TW201625243A (zh) 用於治療黑素瘤之藥物組合
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN105476996B (zh) 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
KR101916283B1 (ko) 암에 대한 방사선 치료 증진용 약학적 조성물
KR102285938B1 (ko) 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 조성물
KR102363043B1 (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102063398B1 (ko) Pfi-3를 포함하는 신장암의 예방 또는 치료용 조성물
KR102844410B1 (ko) 카르니틴 아실카르니틴 운반자 억제제 및 퍼옥시좀 베타 산화 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
AU2024226274A1 (en) Pharmaceutical for treating or preventing chemotherapy-induced peripheral neuropathy
AU2024225878A1 (en) Pharmaceutical for treating or preventing peripheral neuropathy
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
TWI794847B (zh) 用於減少代謝症候群之組合物及其應用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13857414

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2014548630

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13857414

Country of ref document: EP

Kind code of ref document: A1